The PROMISE study: A phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de Novo kidney transplantation

American Journal of Transplantation

Volumn 11, Issue 12, 2011, Pages 2675-2684

  Busque, S ^a   Cantarovich, M ^b   Mulgaonkar, S ^c   Gaston, R ^d   Gaber, A O ^e   Mayo, P R ^f   Ling, S ^f   Huizinga, R B ^f   Meier Kriesche, H U ^g  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c SAINT BARNABAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e HOUSTON METHODIST HOSPITAL   (United States)

^f Isotechnika Pharma Incorporation ^*  (United States)

^g UNIVERSITY OF FLORIDA   (United States)

Author keywords

Acute rejection; calcineurin inhibitor agents; clinical trials; new onset diabetes mellitus; pharmacodynamics of immunosuppressive agents; pharmacokinetics of immunosuppressive agents; renal transplant

Indexed keywords

METHYLPREDNISOLONE; MYCOPHENOLIC ACID; TACROLIMUS; VOCLOSPORIN;

ACUTE GRAFT REJECTION; ADULT; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; FEMALE; FEVER; GINGIVA HYPERPLASIA; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HAIR GROWTH; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INSOMNIA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; PARESTHESIA; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; POLYOMA VIRUS INFECTION; POSTOPERATIVE DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREMOR; URINARY TRACT INFECTION; VOMITING;

CARDIOVASCULAR DISEASES; CYCLOSPORINE; DIABETES COMPLICATIONS; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SURVIVAL RATE; TACROLIMUS;

EID: 82455171878     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03763.x     Document Type: Article

References (22)

1. Ekberg H, Grinyõ J, Nashan B, et al,. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 2007; 7: 560-570. (Pubitemid 46376436)
2. Johnson R, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J,. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-786. (Pubitemid 32879845)
3. Larson T, Dean P, Stegall M, et al,. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522. (Pubitemid 43382137)
4. Einecke G, Sis B, Reeve J, et al,. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
5. Gaston R, Cecka J, Kasiske B, et al,. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
6. Dumont F,: ISAtx-247 (Isotechnika/Roche). Curr Opin Investig Drugs 2004; 5: 542-550.
7. Bërsan T, Dambrin C, Freitag D, Yatscoff R, Morris R,. The novel calcineurin inhibitor ISA247: A more potent immunosuppressant than cyclosporine in vitro. Transplant Int 2005; 17: 767-771. (Pubitemid 41187416)
8. Abel MD, Aspeslet L, Freitag D, Trepanier D, et al,. ISATX247: A novel calcineurin inhibitor. J Heart Lung Transplant 2001; 20: 161.
9. Yatscoff R, Abel M, Aspeslet L, et al,. Phase 2 randomized, multicenter, open-label study of ISA247 and Neoral in post-renal transplant patients [Abstract 1215]. Am J Transplant 2003; 5: 463.
10. Papp K, Bissonnette R, Rosoph L, et al,. Efficacy of ISA247 in plaque psoriasis: A randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008; 371: 1337-1342. (Pubitemid 351522314)
11. Bissonnette R, Papp K, Poulin Y, et al,. A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J Am Acad Dermatol 2006; 54: 472-478. (Pubitemid 43243451)
12. Genuth S, Alberti KG, Bennett P, et al,. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
13. Racusen L, Solez K, Colvin R, et al,. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723. (Pubitemid 29082898)
14. Busque S, Leventhal J, Brennan D, et al,. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: A pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9: 1936-1945.
15. Vincenti F, Larsen C, Durrbach A, et al,. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781. (Pubitemid 41215486)
16. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
17. Durrbach A, Pestana J, Pearson T, et al,. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-557.
18. Ekberg H, Bernasconi C, Tedesco-Silva H, et al,. Calcineurin inhibitor minimization in the symphony study: Observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876-1885.
19. Vincenti F, Friman S, Scheuermann E, et al,. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506-1514. (Pubitemid 46776239)
20. Heit J, Apelqvist AA, Gu X, et al,. Calcineurin/NFAT signaling regulates pancreatic ß-cell growth and function. Nature 2006; 443: 345-349. (Pubitemid 44435154)
21. Øzbay LA, Smidt K, Mortensen DM, Carstens J, Jørgensen KA, Rungby J,. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol 2011; 162: 136-146.
22. Grinyõ J, Ekberg H, Mamelok R, et al,. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: The Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009; 24: 2269-2276.